FEB 11, 2021 8:00 AM PST

Seeing if Hormone Therapy Will Work for Breast Cancer Patients

WRITTEN BY: Tara Fernandez

Only around half of the women diagnosed with breast cancer will benefit from hormonal therapy, a cancer treatment that adds, blocks, or removes specific hormones to stall the growth and spread of breast cancer cells. The women who respond to these therapies are hormone receptor-positive, meaning that the breast tumor cells carry functional receptors for estrogen or progesterone or both. 

The problem is that until now, there is no simple and reliable way to determine whether a patient falls into the responder or non-responder category.

“If breast cancer in a patient is estrogen receptor-positive, doctors will usually recommend hormone therapy even though they know it will only work for slightly more than half the patients,” explained radiology expert Farrokh Dehdashti from Washington University in St. Louis.

“When hormone therapy works, it’s typically quite effective, and it has milder side effects than some other therapies, and that’s why oncologists and patients want to try it first. But we need to narrow down who is likely to benefit, and there really hasn’t been a reliable test to accomplish that.”

Dehdashti and colleagues have published a study in Nature Communications that describes a novel imaging procedure that could soon allow health care professionals to “see” whether a patient would stand to benefit from hormone therapy.

The test leverages a unique relationship between the estrogen and progesterone receptors. If the estrogen receptors are active, once stimulated, they trigger the breast cancer cell to react by increasing the number of progesterone receptors on the cell surface.

The team collaborated with chemist John Katzenellenbogen from the University of Illinois, who created an imaging agent that can quantify how many progesterone receptors are being expressed on the breast tumor. This agent, called 21-[18F] fluorofuranylnorprogesterone (FFNP), latches on to the progesterone receptor and can be imaged using a positron emission tomography (PET) scanner.

This newly-developed imaging technology was validated in a cohort of breast cancer and demonstrated that the technique could be used to predict which of them would respond to hormone therapy accurately.

“We observed 100% agreement between the response to estrogen challenge and the response to hormone therapy, even though the participants were on a variety of treatment regimens,” said Dehdashti. 

“This method should work for any therapy that depends on a functional estrogen receptor, and it could provide valuable information to oncologists deciding how best to treat their patients.”

 

 

Sources: Nature Communications, Washington University in St. Louis.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
DEC 22, 2020
Cardiology
A New 3D Imaging Method for Atherosclerosis Analysis in Mice
DEC 22, 2020
A New 3D Imaging Method for Atherosclerosis Analysis in Mice
Imaging in research may not sound glamorous, but how else would news stories get those cool looking science photos for t ...
DEC 31, 2020
Clinical & Molecular DX
Silent Mice Drive Autism Gene Discovery
DEC 31, 2020
Silent Mice Drive Autism Gene Discovery
Around 1 in 54 children in the U.S. are diagnosed with autism spectrum disorder, or ASD, a broad range of conditions tha ...
JAN 14, 2021
Cardiology
Cortisol in Your Hair Could Predict Your Risk of Heart Attack
JAN 14, 2021
Cortisol in Your Hair Could Predict Your Risk of Heart Attack
The everyday tracking of health has become far easier these days with the advent of fitness watches and other technology ...
JAN 13, 2021
Clinical & Molecular DX
E-Stethoscope Picks up Good (and Bad) Vibrations
JAN 13, 2021
E-Stethoscope Picks up Good (and Bad) Vibrations
A medical device used to survey lung sounds to monitor for signs of respiratory distress has received FDA clearance. RES ...
JAN 26, 2021
Clinical & Molecular DX
Prostate Cancer Screening: No More False Positives
JAN 26, 2021
Prostate Cancer Screening: No More False Positives
A new diagnostic test powered by artificial intelligence has been found to detect prostate cancer markers in urine sampl ...
JAN 31, 2021
Genetics & Genomics
Targeting Aneuploidy in Cancer Cells
JAN 31, 2021
Targeting Aneuploidy in Cancer Cells
Cancer is typically related to problems in cells' genomes that lead to uncontrolled cell growth, and the formation of tu ...
Loading Comments...